Richard JM Ross, Professor of Endocrinology, Faculty Academic Lead for Innovation and Head of Unit Diabetes, Endocrinology & Metabolism, University of Sheffield, UK Abstract
Richard Ross trained in Medicine at The Royal London Hospital (19741979) and in Endocrinology at St Bartholomew's Hospital, London (19831988). He was appointed to Sheffield University in 1995 and is Professor of Endocrinology and Head of the Unit of Diabetes, Endocrinology and Metabolism.
Richard's research and clinical interests are in pituitary disease, transition endocrinology and the late effects of cancer. His research has yielded some 120 papers, 50 chapters, 2 books, and over 20 granted patents. Richard has a particular interest in commercial research and is the Faculty Academic Lead for Innovation. He is a founding Director of two university spin-out companies; Asterion Ltd developing long-acting growth hormone analogues and Diurnal Ltd developing circadian endocrine therapies. He personally obtained Orphan Drug Designation for Chronocort; a new therapy for Adrenal Insufficiency.
He has served on the editorial boards of: Clinical Endocrinology (19962000), Growth & Growth Factors (19862006), Hormones (2004), and Journal of Clinical Endocrinology and Metabolism (2010). He was a council member for the Society of Endocrinology (19992002), Editor of the Endocrinologist (20012004), Chair of CaHASE (2002), member of the Bioscientifica Board (20062010) and serves on the Executive Committee of the European Society of Endocrinology (2011), The Growth Hormone Research Society Council (2011), Society for Endocrinology Public Engagement Committee (20082011) and Nominations Committee (2010).